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ABSTRACT 
In a prospective open trial, 30 inpatients with catatonic signs were treated systematically 
with oral lorazepam (dosage ranging between 3 to 8 mg/d) for a period of 5 days and subsequently 
with ECT if lorazepam trial failed. Outcome was monitored quantitatively during the treatment 
phase with Bush-Francis catatonia rating scale. In 21 out of 30 patients (70%), catatonic signs 
resolved with lorazepam trial. The response to lorazepam on Day 1, predicted the final outcome. 
Demographic variables, severity of catatonia or length of catatonic syndrome prior to treatment 
did not have any predictive value. Majority of the patients who showed an unfavourable response, 
did well with electroconvulsive therapy. A short duration lorazepam administration proved to be a 
safe and effective treatment for the catatonic syndrome. 
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The term "catatonia" was first described 
by Karl Kahlbaum in an 1874 monograph (Levi 
& Pridon, 1973). In addition to occurring as a 
part of an affective disorder, schizophrenic 
disorder, and brief psychotic illnesses, this 
syndrome can result from multiple organic 
states. Regardless of its cause, catatonia may 
be associated with significant morbidity and 
mortality from medical complications. Hence 
timely diagnosis and management are of utmost 
importance. Though ECT remains a powerfully 
effective and lasting treatment for cataionia in 
cases where organic causes are ruled out (Bush 
et al. 1996b), many studies have supported the 
usetitf benzodiazepines in the management of 
catatonia. 
Fricchione et al. (1983) reported on the 
benefit of intravenous lorazepam in neurolep-
tic induced catatonic states including neurolep-
tic malignant syndrome. Walter-Ryan(1985) 
used intramuscular lorazepam in three schizo-
phrenic patients with catatonia with significant 
response. Heuser and Bendort (1986) reported that 
single oral doses of lorazepam were successful in 
short-term alleviation of mutism. Vinogradov and 
Reiss (1986) successfully employed alternating oral 
and intramuscular doses of lorazepam in a treat-
ment resistant catatonic bipolar patient. Weltz et 
al. (1987) reported the therapeutic benefit of 
lorazepam when given orally to a catatonic 
woman with recurrent major depression. Salam 
and Reiss (1988), have reported on successful 
use of parenteral lorazepam in three of five psy-
chogenic catatonic patients. Menza and Harris 
(1989), concluded that benzodiazepines trial 
should be considered in patients with suspected 
psychogenic catatonia as long as no 
contraindication exists such as seriously 
increasing risk of respiratory or hepatic failure 
A recent study by Bush et al (1996b) reported 
the benefit of lorazepam in amelioration of 
catatonic signs. Weltz and Benkert (1988), while 
using both diazepam and lorazepam found a 
more favourable response with lorazepam. 
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In India no systematic study has been 
done to evaluate the role of lorazepam in 
amelioration of catatonic symptoms. The 
present study has been designed to study the 
effectiveness of oral lorazepam in resolving 
catatonic signs and symptoms as well as look 
for predicators of response to lorazepam. 
MATERIAL AND METHOD 
All inpatients admitted to the Psychiatry 
unit of JIPMER, Pondicherry, were screened for 
catatonia over a period of 15 months between 
1st December 1996 to 31st March 1998. 
Consecutive admissions were prospectively 
screened using Bush-Francis Catatonia 
Screening Instrument (Bush et al., 1996a). This 
screening instrument has 14 items, out of which 
at least 2 items should be present to diagnose 
catatonia The only exception to this was when 
stupor was present alone, catatonia was still 
diagnosed (Benegal et al., 1992). Patients on 
antipsychotic drugs, those with concurrent medi-
cal illnesses like parkinsonism and 
encephalopathy etc. and those with past 
history of psychiatric illness were excluded from 
the study. The cases were evaluated for sever-
ity of catatonia using the 23 item Bush-Francis 
catatonia rating scale following the guidelines 
outlined in the standardised examination method 
for catatonia (Bush et al., 1996a). As a part of 
the routine admission procedure all subjects 
were given a diagnostic work up including com-
plete physical and neurological examination as 
well as routine laboratory tests. EEG recording 
and CT scan examination were done when org-
anicity was suspected. 30 cases of catatonia 
thus identified comprised the study sample. 
Owing to their catatonic state the patients had 
a very limited understanding of the situation and 
treatment offered to them. Consent was ob-
tained from the patients relatives in accordance 
with the accepted procedure for stuporous pa-
tients (McCall et al., 1992). Following the diag-
nostic workup, baseline ratings to assess se-
verity of catatonia were done. All the patients 
were administered tab. lorazepam (oral / via 
Ryle's tube) 3 mg on day 1, 6 mg on day 2 and 
if treatment response was inadequate the dose 
was further increased to 8 mg till day 5. The 
assessments were repeated on a daily basis for 
a period of 5 days. Response was defined as 
reduction of catatonic signs to 1 or none on 14 
item BFCSI. Failures were defined as patents 
who continued to display two or more signs of 
catatonia after 5 days of treatment with 
lorazepam, had worsening of clinical or nutri-
tional status due to severe persistent catatonia. 
All ratings were done during evening hours by 
two raters (HP and RC) independently. 
Discrepancies were overcome by adopting a 
consensus method. The non responders were 
treated with ECT using modified brief pulse 
bilateral electrode placement following routine 
treatment protocol. The mean number of ECTs 
administered was 6.33 per patient (Range 
3-9). Routine administration of neuroleptic were 
avoided during the lorazepam trial period. 
Subsequently patients were prescribed drugs ac-
cording to clinical requirements. 
Statistics 
The statistical comparison between 
treatment response and some basic 
demographic and clinical variable were 
computed using 2 tailed t test, X
2 test and 
Man-Whitney U test. 
RESULT 
The study population consisted of 16 
women and 14 men. Their mean age was 25 
years (range 16-40 years); mean number of 
years spent in school was 10.8±2.33 years; all 
belonged to lower middle socioeconomic 
status. The final diagnoses according to 
ICD-10 are given in table 1. The various diag-
noses in the study sample were: Acute and tran-
sient Psychotic Disorder (N=12), Unspecified 
Non Organic Psychosis (N=10), Schizophrenia 
(N=6), Severe Depression (N=2). The distribu-
tion frequency of catatonic symptoms in the 
sample studied are as follows : Mutism (29), 
Rigidity (28), Negativism (25), Immobility/Stu-
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TABLE 1 
CLINICAL DIAGNOSIS ACCORDING TO ICD-10 
Diagnostic group  No. of Patients 
Acute and transient psychotic . 
disorders (F 23 0) 
Unspecified non organic 
psychosis (F 29.0) 
Schizophrenia (F 20.0) 
Depressive episode 
12/30 
10/30 
6/30 
2/30 
Percentage 
40% 
33.3% 
20% 
6.6% 
por(23), Posturing (22), Staring (21), Withdrawal 
(21), Waxy flexibility (12), Autonomic abnormal-
ity (7), Ambitendency (3) and Grimacing (2). 
Other catatonic signs, echopraxia, excitement, 
impulsivity, combativeness, qegenhalten oc-
curred in one patient each. 
21 patients (70%) were considered as 
responders and 9 (30%) as non responders af-
ter 5 days of lorazepam trial. The characteris-
tics of responders and non responders are given 
in table 2. The drop in catatonia score by the 
end of day 1, had a predictive value in differen-
tiating responders from non responders. The 
severity of catatonia, age, sex, length of illness, 
duration of catatonia and clinical diagnosis, 
didn't influence the outcome. 9 out of 30 pa-
tients of initial cohort needed ECT as none of 
them showed further improvement in their cata-
tonic state with lorazepam despite 5 days of 
treatment. All patients except one, responded 
to ECT. 
DISCUSSION 
The data from this study shows that 
catatonic signs are found to be more frequently 
associated with acute and transient psychotic 
disorders (40%). This is closely followed by 
psychosis NOS (33.3). The psychosis NOS 
group closely resembles the idiopathic catato-
nia described by Benegal et al. (1993) where 
no other psychotic syndrome could be clearly 
identified after the resolution of catatonia. 
Earlier studies by Abrams and Taylor (1976), 
Rosebush et al. (1990), Bush et al. (1996b) 
showed strong association between affective 
disorders particularly mania, but our study has 
not confirmed this association. Depressive epi-
sodes were diagnosed in only two cases and 
mania in none. Another Indian study (Banerjee 
and Sharma, 1995) reported higher percentage 
of acute and transient psychotic disorders in their 
catatonic population. A slightly higher represen-
tation of schizophrenic diagnoses was found in 
our study compared to the earlier studies. This 
possibly confirms the view of Sartorius et al. 
(1986) that catatonic subtypes of schizophre-
nia is more frequently observed in developing 
TABLE 2 
CLINICAL CHARACTERISTICS : RESPONDERS VS NON RESPONDERS 
Characteristics 
Age 
Gender 
(women/total) 
Catatonic score (baseline) 
Duration of catatonia (days) 
% Drop in baseline score 
Responders 
<N=21) 
24.45*4.1 
12 
15.50 (MR.) 
12.85 (M.R.) 
17.83 (MR.) 
Non responders 
(N=9) 
27.8±3.2 
9 
15.5 (MR.) 
20.80 (MR.) 
10.85 (MR.) 
Test applied 
t-test 
Chi square test 
Man-Whitney 
Utest 
Man - Whitney 
Utest 
Man - Whitney 
Utest 
Significance 
NS 
NS 
NS 
Significance" 
Significance** 
M.R. = Mean Rank 
** =2 tailed p < 0.05 
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countries. 
There is an evidence to support the view 
that lorazepam is useful in alleviating catatonic 
signs, confirming the findings of the earlier stud-
ies (Rosebush, 1990; Ungvari et al., 1994). The 
study had shown that the drop in BFCRS score 
at the end of day 1 predicted the final outcome 
of a five-day treatment with lorazepam. There 
was no relationship between the severity of cata-
tonia as well as the total number of catatonic 
signs cind the final outcome. This is in agree-
ment with the findings of Abrams and Taylor 
(1976) and Bush et al. (1996b). Another vari-
able, the duration of catatonia prior to treatment, 
shown to have a predictive value (Bush et al., 
1996b) was not confirmed in this study. 
In spite of the shortcomings of this study 
such as lack of a controlled double blind design 
and a small sample size, the clinical usefulness 
of lorazepam has been clearly established in 
our patients providing varying degrees of instan-
taneous subjective relief. It certainly alleviates 
the severity of catatonia and allows the clini-
cian to extend the diagnostic interview, com-
plete the investigations and obtain consent to 
clear the legal formalities if ECT becomes nec-
essary. Catatonia has not become rare. Short 
tasting and transient catatonic signs are com-
jvionly found in acutely ill psychiatric patients. 
Lorazepam is safe and.effective in alleviating 
catatonic symptoms. No respiratory problem 
was encountered in any of the catatonic patients 
treated with lorazepam. Nevertheless better 
guidelines need to be established regarding the 
duration of its use and the dosage range required 
to produce sustained effects. 
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